Lifeward Ltd.

LFWD · Nasdaq · Israel

Share price · LFWD

$3.20-4.21 (-56.80%) 3M

close as of 2026-11-18 · 24h delayed · vol 14K (0.7x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when LFWD's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 17 Nov 2026-14.4%
  2. 13 Nov 2026-29.0%
  3. 5 Oct 2026+14.0%
  4. 1 Oct 2026-9.7%
  5. 8 Sep 2026+6.0%
  6. 6 Jul 2026+8.9%

    Nothing announced by LFWD that day or the session before.

  7. 30 Jun 2026+7.4%
  8. 22 May 2026+11.2%
  9. 20 Apr 2026+10.8%

    Nothing announced by LFWD that day or the session before.

  10. 27 Feb 2026+14.4%

Share of unusual movement by asset

For each asset, the share of LFWD's own-move activity since 14 Oct 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Other company news (earnings, financing, releases naming no asset)—16%
Sessions with no dated event—84%

No dated announcements about its assets since 14 Oct 2025.

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 3
InsulinPeptide
Type 2 DiabetesMASH / NASH

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (15)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$5.4M$1.9M$5.0M$5.0M-$6.4M operating cash flowreport ↗
View 14 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$6.6M$1.8M$9.9M$12M-$6.0M operating cash flowreport ↗
2026-Q1$3.9M$5.8M$12M$11M-$3.7M operating cash flowreport ↗
2025-Q3$6.2M$0.7M$2.4M$3.2M-$3.8M operating cash flowreport ↗
2025-Q2$5.7M$0.8M$5.5M$6.6M-$3.9M operating cash flowreport ↗
2025-Q1$5.0M$0.9M$6.1M$4.8M-$5.5M operating cash flowreport ↗
2024-Q3$6.1M$1.0M$11M$3.1M-$4.5M operating cash flowreport ↗
2024-Q2$6.7M$1.2M$15M$4.3M-$5.6M operating cash flowreport ↗
2024-Q1$5.3M$1.3M$21M$6.3M-$7.7M operating cash flowreport ↗
2023-Q3$4.4M$1.3M$33M$7.5M-$7.4M operating cash flowreport ↗
2023-Q2$1.3M$0.8M$59M$4.6M-$3.5M operating cash flowreport ↗
2023-Q1$1.2M$0.8M$63M$4.3M-$5.2M operating cash flowreport ↗
2022-Q3$0.9M$1.1M$75M$5.5M-$4.6M operating cash flowreport ↗
2022-Q2$1.6M$1.0M$79M$4.5M-$3.7M operating cash flowreport ↗
2022-Q1$0.9M$0.9M$83M$4.3M-$5.7M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$22M$3.3M$2.6M$5.0M-$17M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$26M$4.6M$7.1M$7.2M-$22M operating cash flowreport ↗
2023-FY$14M$4.2M$29M$5.5M-$21M operating cash flowreport ↗
2022-FY$5.5M$4.0M$69M$4.9M-$18M operating cash flowreport ↗
2021-FY$6.0M$2.9M$89M$3.2M-$11M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-08-20Gabay Avraham · directorAward / grant13,643——Form 4
2026-08-14Zamir Haggai · directorAward / grant6,711——Form 4
2026-08-14Greenwald Yonason · directorAward / grant6,711——Form 4
2026-05-01Rose Keith Dale · Chief Medical OfficerAward / grant15,000——Form 4
2026-03-25Rozenbaum Moshe H · directorAward / grant11,485——Form 4
2026-03-25Sigsbee William Mark · directorAward / grant11,485——Form 4
2026-03-25Kidron Miriam · directorAward / grant7,657——Form 4
2026-03-25KIDRON NADAV · directorAward / grant7,657——Form 4